Adebrelimab Combined With Fluzoparib in HRD-positive HR +/HER2- Advanced Breast Cancer

NCT06254066 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

40

Enrollment

OTHER

Sponsor class

Conditions

Female Breast Cancer Patients
Histopathologically Confirmed Advanced HR +/HER2-invasive Breast Cancer
HRD Positive Advanced Breast Cancer

Interventions

DRUG: Adebrelimab plus Fluzoparib

Sponsor

Zhejiang Cancer Hospital

Collaborators

[object Object]